LncRNA LOXL1-AS1 expression in cancer prognosis: A meta-analysis

Several studies showed that LncRNA LOXL1 antisense RNA 1 (LOXL1-AS1) is overexpressed in a variety of cancers and plays a role as an oncogene in cancer. The present meta-analysis aims to elucidate the relationship between LOXL1-AS1 expression and prognosis and clinicopathological features among canc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medicine (Baltimore) 2022-12, Vol.101 (52), p.e32436-e32436
Hauptverfasser:	Wang, Xuhua, Chen, Zhaoyuan, Zhou, Huaqiang, Liu, Wuyang, Luo, Jiaquan
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Oxidoreductases - genetics Amino Acid Oxidoreductases - metabolism Biomarkers, Tumor - genetics Humans Lymphatic Metastasis Neoplasms Prognosis RNA, Long Noncoding - genetics Systematic Review and Meta-Analysis Up-Regulation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Several studies showed that LncRNA LOXL1 antisense RNA 1 (LOXL1-AS1) is overexpressed in a variety of cancers and plays a role as an oncogene in cancer. The present meta-analysis aims to elucidate the relationship between LOXL1-AS1 expression and prognosis and clinicopathological features among cancer patients. PubMed, Web of Science, Cochrane Library, and EMBASE database were comprehensively and systematically searched. Pooled odds ratios (ORs) and hazard ratios with a 95% confidence interval (CI) were employed to assess the relationship between LOXL1-AS1 expression and clinical outcomes and clinicopathological features in cancer patients. The present study finally enrolled 8 studies which included 657 cancer patients. The combined results indicated that the overexpression of LOXL1-AS1 was significantly associated with shorter overall survival (pooled hazard ratio = 1.99, 95% CI 1.49-2.65, P
ISSN:	1536-5964 0025-7974 1536-5964
DOI:	10.1097/MD.0000000000032436